PD-1

[Nature Communications] Investigators comprehensively analyzed peripheral blood and/or synovial fluid samples from 20 patients with immune-related adverse events, including arthritis, and unmasked a prominent Th1-CD8+ T cell axis in both blood and inflamed joints.

[IO Biotech] IO Biotech, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win® technology platform, announced that it has dosed the first patient, in metastatic non-small cell lung cancer, in its Phase II IOB-022 / KN-D38 trial.

[Cell Death Discovery] Scientists identified a novel circular RNA (circ_0004140), derived from the oncogene YAP1, which was up-regulated in lung adenocarcinoma (LUAD). The high expression of circ_0004140 was correlated with poor prognosis and cytotoxic T-lymphocyte cells dysfunction in LUAD patients.

[Signal Transduction and Targeted Therapy] The authors unveiled a novel mechanism of the endogenous cannabinoid system-mediated suppression on T cell immunity against cancer, and suggested that cannabis and cannabinoid drugs should be avoided during immunotherapy.

[eLife] The authors demonstrated that homology cluster analysis of T cell receptor (TCR) repertoires efficiently identified tumor-reactive TCRs.

[Ribon Therapeutics] Ribon Therapeutics announced the first patient has been dosed in the Phase Ib/II study of RBN-2397 in combination with the anti-PD-1 checkpoint inhibitor therapy, pembrolizumab, in patients with squamous cell carcinoma of the lung.